BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Merck  Sharp  &  Dohme  Ltd.  submitted  on  3  September  2007  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  TESAVEL,  through  the 
centralised procedure according to Regulation (EC) No 726/2004.  
The legal basis for this application refers to Article 10(c) of Directive 2001/83/EC, as amended, 
relating to informed consent from the marketing authorisation holder, Merck Sharp & Dohme Ltd, for 
the authorised medicinal product Januvia (EU/1/07/383/001-018). 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The initial product, Januvia, has been given a Community Marketing Authorisation on 21 March 2007. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: Pieter de Graeff  Co-Rapporteur: Harald Enzmann 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
The application was received by the EMEA on 3 September 2007. 
The procedure started on 16 September 2007.  
The Rapporteur's first Assessment Report was circulated to all CHMP members on 18 October 
2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 18 
October 2007.  
During  the  meeting  on  12-15  November  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  to  TESAVEL  on  15  November  2007.  The  applicant 
provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation 
on 14 November 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 10 January 2008. 
@EMEA 2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
